Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

HALOBETASOL PROPIONATE & TAZAROTENE

All products: general benefit

Other products in the same Health Canada class (D05AX) — coverage varies; not interchangeable

  • Betamethasone dipropionate + calcipotriol (Dovobet): general benefit
  • Calcipotriol (Dovonex): limited Use 191
  • Calcitriol (Silkis): limited Use 191
  • Tazarotene (Arazlo): limited Use 636

Duobrii · DIN 02499967 · 0.01% & 0.045% · Lot

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Duobrii · DIN 02499967 Manufacturer: Bausch Health Canada Inc.; listing date 2022-01-31 Health Canada: Marketed since 2020-08-04 · brand DUOBRII · ATC D05AX05 TAZAROTENE · form Lotion · route Topical · ingredients HALOBETASOL PROPIONATE 0.01 %/W/W, TAZAROTENE 0.045 %/W/W · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Duobrii: Formulary list price $1.9300/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.9300 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98967 · Verify on the e-Formulary ↗ (DIN 02499967)

Source record
DIN 02499967: Duobrii Raw flags: sec3=Y Item: 849200006; group id 872; item number 2110; lccId None; manufacturer id BHC Source form: Lot; strength: 0.01% & 0.045% Recorded listing: General benefit Source prices (unrounded): $1.9300; ministry $1.9300 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02499967 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98967
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (84:00 SKIN AND MUCOUS MEMBRANE PREPARATIONS) and how they are covered

Matched class: 84:00 SKIN AND MUCOUS MEMBRANE PREPARATIONS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ACITRETIN, AZELAIC ACID, BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE, DIMETHICONE., FLUOROURACIL, FUSIDIC ACID, HALOBETASOL PROPIONATE, ISOPROPYL MYRISTATE, ISOTRETINOIN, METRONIDAZOLE & NYSTATIN, MICONAZOLE NITRATE, MOMETASONE FUROATE, MUPIROCIN CALCIUM, PERMETHRIN, PYRETHRINS & PIPERONYL BUTOXIDE, SILVER SULFADIAZINE, SODIUM FUSIDATE, TERBINAFINE HCL, ZINC SULFATE Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, CLOTRIMAZOLE, COLLAGENASE, DESONIDE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, KETOCONAZOLE, METRONIDAZOLE, MUPIROCIN, NYSTATIN, TERCONAZOLE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE 84:00 SKIN AND MUCOUS MEMBRANE PREPARATIONS

TAZAROTENE

· 1 products · Limited Use, codes 636 · strengths: 0.045% w/w · Lot

BIMEKIZUMAB

· 4 products · Limited Use, codes 641 · strengths: 160mg/mL, 320mg/2mL · Inj Sol-1mL Pref Autoinj (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free), Inj Sol-2mL Pref Autoinj (Preservative-Free), Inj Sol-2mL Pref Syr (Preservative-Free)

GUSELKUMAB

· 2 products · Limited Use, codes 658 · strengths: 100mg/mL · Inj Sol-1mL Autoinj (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free)

TILDRAKIZUMAB

· 1 products · Limited Use, codes 629 · strengths: 100mg/mL · Inj Sol-1mL Pref Syr (Preservative-Free)

ACYCLOVIR

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5% · Top Oint Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:00 84:04:04 Antibiotics

CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE

· 4 products · General benefit · strengths: 1% & 5% · Gel, Top Gel

FUSIDIC ACID

· 2 products · General benefit · strengths: 2% · Cr

MUPIROCIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Oint

MUPIROCIN CALCIUM

· 1 products · General benefit · strengths: 2% w/w · Cr

SODIUM FUSIDATE

· 2 products · General benefit · strengths: 2% · Oint

CLINDAMYCIN PHOSPHATE & ADAPALENE & BENZOYL PEROXIDE

· 1 products · Limited Use, codes 724 · strengths: 1.2% w/w & 0.15% w/w & 3.1% w/w · Top Gel Pump

CLINDAMYCIN

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% · Top Sol Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:04 and 53 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS DUOBRII (halobetasol propionate and tazarotene lotion), is indicated for: • Improving the signs and symptoms of plaque psoriasis in adult patients with moderate to severe plaque psoriasis. 1.1 Pediatrics Pediatrics (under the age of 18 years) The safety and efficacy of DUOBRII in pediatric patients have not been established; therefore, DUOBRII is not indicated for pediatric use (see WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics). 1.2 Geriatrics Geriatrics (> 65 years of age) A limited number of subjects aged > 65 years have been treated with DUOBRII in clinical trials, therefore the safety and efficacy have not been established in this patient population (see WARNINGS AND PRECAUTIONS, Special Populations, Geriatrics). https://pdf.hres.ca/dpd_pm/00082162.PDF PM date: June 17, 2022 Source product: DUOBRII; DIN 02499967; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.